By the end of September I believe all debt will be converted. After all debt is converted there will be 16.5 million shares outstanding.
In terms of how much of a return, you've asked that numerous times. And the truth is I don't know!!
That depends on a few things:
first: how many shares will IPO when they up list to the nasdaq. After converting all debt they will have 16.5 million outstanding, however; how many additional shares will they sell? 33.5 million is what I hope, but it could be more. Let's say they IPO 83.5 instead, resulting in 100 million outstanding, in that case the highest the stock could go to is $100 a share. At 50 million outstanding, it could reach $200 a share, and at 150 outstanding, it could reach $66.67 a share. We won't know how many shares they'll have outstanding until they finish converting the debt and also IPO shares on the nasdaq that'll fund the trials. The good news is, after they IPO shares on the nasdaq, I don't think they'll have to sell additional shares after, because the funding from the IPO should provide them with enough money for the next 1-1.5 years. And in the fall/winter of next year, PainBrake will have completed the NDA and be on the market, generating revenue for Oxis that they can use to fund continuing trials instead of selling additional shares. Dr.Kathleen talked about this on the conference call as I'm sure you know.
Additional note: I just like you have sold my position, and am looking forward to when all debt is converted so I can come back in and purchase shares. For those of you currently holding, this stock will be under $1 by the end of next week so you really should sell and then come back in. At the end of September this will pop once the CMO is revealed so make sure to get back in before that.
The stock will be doing very well by November/December. At this point, the CMO whom previously was the CMO of Pfizer will be announced, PainBrake will be less than 12 months away from approval!! , all debt will have been converted leaving Oxis with a clean balance sheet, and Oxis will be trading on the NASDAQ. Also by this time two TriKEs will have entered the clinic with updates on how the liquid tumor 161533 compound being released. And OXS-1550 Phase II data will be available in just two/three months.
MrBond007, If by December, Oxis out-licenses the TriKE platform (which they stalked about in the conference call) and they sell PainBrake (hopefully by Christmas). Then as you say Oxis to the moon, baby!!!!!! the stock will be doing amazing. How could it not, a diabetic neuropathic drug that causes complete pain relief and is a year away from approval, a CMO who was previously the CMO of Pfizer! One of the largest pharmaceuticals companies in the world. The highly valued TriKE for liquid tumors will have entered the clinic. With results being publicly announced, AND AGAIN they can out-license the TriKE platform which has the potential to bring in millions! And the new CEO in the conference call said she has interest in acquiring more close to NDA approval CNS drugs!!!!
OXIS TO THE MOON BABY!!!!!!!!!!!
